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Site-selected incorporation of 5-carboxymethyl-
aminomethyl(-2-thio)uridine into RNA sequences
by phosphoramidite chemistry†
Grazyna Leszczynska,* Jakub Pięta, Karolina Wozniak and Andrzej Malkiewicz
5-Carboxymethylaminomethyluridine (cmnm5U) and 5-carboxy-
methylaminomethyl-2-thiouridine (cmnm5s2U) are located at the
wobble position in several cytosolic and mitochondrial tRNA
sequences. In this paper, we report the ﬁrst site-selected incorpor-
ation of cmnm5U and cmnm5s2U into RNA sequences by phos-
phoramidite chemistry on a CPG solid support. Triﬂuoroacetyl and
2-(trimethylsilyl)ethyl were selected for the protection of the
amine and carboxyl functions, respectively.
Several C-5 substituted (2-thio)uridines are native components
of tRNAs isolated from prokaryotic and eukaryotic cells,
including mitochondrial tRNAs (mt-tRNAs).1 5-Carboxymethyl-
aminomethyluridine (cmnm5U, 1, Fig. 1a) and 5-carboxy-
methylaminomethyl-2-thiouridine (cmnm5s2U, 2, Fig. 1a) are
located at position 34 (“wobble” position, the first anticodon
letter) of Saccharomyces cerevisiae mt-tRNAs specific for Leu
and Lys, respectively (Fig. 1c).1,2 Interestingly, the structurally
related pair of “wobble” (2-thio)uridines modified at C-5 with
the methylene–taurine residue, that is, 5-taurinomethyluridine
(τm5U, 3, Fig. 1b) and its 2-thio analogue (τm5s2U, 4, Fig. 1b),
are characteristic of human mt-tRNA (hmt-tRNA) sequences
specific for Leu(UUR) and Lys, respectively.1,3
Nucleosides 1–4 play a crucial role in the translation pro-
cesses that restrict mt-tRNA decoding capacity to A and G as
the third codon letter.2,4,5 The presence of C-5 glycine and
taurine residues in the structure of nucleosides 1–4 seems to
be important for decoding G,4–6 while the lack of both 5-sub-
stituents and the 2-thio group totally stalls the translation
machinery.4–7
It is noteworthy that the point mutations 3243(A → G) in
the hmt-tRNALeu gene and 8344(A → G) in the hmt-tRNALys
gene induce the loss of τm5U and τm5s2U, respectively, which
results in incurable mitochondrial diseases (MELAS, MERRF).5
Recently, yeast cells have been suggested as a useful model
for studies of the molecular and cellular eﬀects related to
human mitochondrial diseases.8 Partial correction of the
MERRF and MELAS syndromes was observed after targeting
import of the “chimeric” yeast tRNALys into human
Fig. 1 (a) The structure of 5-carboxymethylaminomethyluridine
(cmnm5U, 1) and 5-carboxymethylaminomethyl-2-thiouridine
(cmnm5s2U, 2). (b) The structure of 5-taurinomethyluridine (τm5U, 3)
and 5-taurinomethyl-2-thiouridine (τm5s2U, 4). (c) The sequence and
secondary structure of the Saccharomyces cerevisiae mitochondrial
tRNALeu and tRNALys anticodon stem and loop (mt-ASLLeuS. cerevisiae,
mt-ASLLysS. cerevisiae) modiﬁed with cmnm
5U and cmnm5s2U, respectively.
The native sequence of mt-ASLLeuS. cerevisiae has three additional modiﬁed
nucleosides: pseudouridines (ψ) at positions 31 and 39 and 1-methylgua-
nosine at position 37. In the native sequence of mt-ASLLysS. cerevisiae there
are two pseudouridines (ψ) at positions 28 and 31, and N-[(9-β-D-ribo-
furanosyl-9H-purin-6-yl)carbamoyl]-L-threonine (t6A) at position 37.
†Electronic supplementary information (ESI) available: General information,
experimental details, spectral characterisation of 11a/11b, 12a/12b, 13a/13b, oligo-
ribonucleotide synthesis, MALDI–TOF spectra. See DOI: 10.1039/c3ob42302f
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mitochondrial cybrid cells.9 It was also demonstrated that
hmt-tRNALys,Leu precursors, equipped with suitable carriers,
are eﬀectively imported to the organelle and processed to
mature tRNAs, in this way rescuing mitochondrial protein
biosynthesis.10
Synthetic modified tRNA fragment(s) have become useful
tools for probing the structural and mechanistic aspects of bio-
polymer activities, particularly in model studies on the struc-
tural restraints of “wobble” pairing.11
Modified oligomers are also used as substrates for enzy-
matic ligation of RNA fragments to generate longer RNA con-
structs.12 The synthesis of cmnm5U and cmnm5s2U, as well as
their conformations in solution and the solid state, have been
reported.13 Using the classical triester approach in solution,
both modified units were built in anticodon triplets related to
tRNALysB. subtilis and tRNA
Gly
B. subtilis.
14 Recently, 5′,3′-O-bisphosphate
of cmnm5U has been used to incorporate this modification
into position 34 of the tRNALeu(UUR) sequence in E. coli via
semienzymatic ligation of RNA fragments.4 In this paper, we
present CPG-supported (phosphoramidite chemistry) synthesis
of 17-mer long RNAs related to the sequence of the anticodon
arm of S. cerevisiae mt-tRNALeu and mt-tRNALys.
Synthesis of RNA fragments modified with cmnm5U and
cmnm5s2U required several interventions in the standard
protocol of phosphoramidite chemistry on a CPG support. In
the chemical structure of nucleosides 1 and 2, there are highly
reactive aliphatic amine and carboxyl functions which should
be protected in a manner compatible with the protection of
the commercially available canonical monomeric units. The
aliphatic amine function was protected with a base labile tri-
fluoroacetyl group, following the methodology elaborated
previously, which was used for incorporation of 5-methylamino-
methyl(-2-thio)uridine (mnm5(s2)U) into RNA fragments.15–18
For the protection of the carboxyl function, removable under
neutral conditions, 2-(trimethylsilyl)ethyl (TMSE) was selected.
The usefulness of this strategy was previously confirmed during
the synthesis of RNAs modified with (2-methylthio)adenosine
bearing a N6-treonylcarbamoyl residue (t6A, ms2t6A).18,19 It is
noteworthy that the TMSE ester is stable under prolonged treat-
ment with ethanolic ammonia and oﬀers a simple and eﬀective
way for simultaneous removal of alkaline labile protecting
groups and cleavage of oligomers from the CPG support
without the risk of amide formation.
The multistep synthesis of the fully protected 5-carboxy-
methylaminomethyl(-2-thio)uridine 3′-O-phosphoramidite 13a/
13b is presented in Scheme 1. For the synthesis of TMSE-pro-
tected cmnm5(s2)U 8a/8b we employed an eﬀective procedure of
reductive amination including 5-formyl(-2-thio)uridine 6a/6b
and 2-(trimethylsilyl)ethyl glycine ester, in the presence
of sodium triacetoxyborohydride (NaBH(OAc)3).
20 For this
purpose, 5-hydroxymethyl-2′,3′-O-isopropylidene(-2-thio)uridine
5a/5b was selectively oxidized with activated MnO2 in acetone–
DCM solution, giving 5-formyl(-2-thio)uridine 6a/6b, which was
used in a reaction with glycine ester in DCM–DMF solution. The
imine 7a/7b, without isolation, was reduced with NaBH(OAc)3.
The crude secondary amine 8a/8b was protected with a
Scheme 1 Reagents and conditions: (i) activated MnO2, acetone–DCM (4 : 1, v/v), 2–7 h, 55 °C; (ii) HCl × NH2CH2COOTMSE, TEA, DCM–DMF, 1.5 h,
rt; (iii) NaBH(OAc)3, 2 h, rt; (iv) TFAA, py, 1.5 h, 0 °C; (v) 25% aq. AcOH, 1 h, 90 °C; (vi) DMT-Cl, py, 16 h, rt; (vii) TBS-Cl, imidazole, py, 4 h, rt; (viii)
[(CH3)2CH]2NP(Cl)OCH2CH2CN, [(CH3)2CH]2NCH2CH3, DCM, 5–7 h, rt.
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trifluoroacetyl group.21 2′,3′-Acetonide 9a/9b was removed under
mild acidic conditions to give the N-protected nucleoside 10a/
10b. The synthesis of 5′-O-DMT-2′-O-TBS-phosphoramidite 13a/
13b followed typical procedures.16 For more details of the pro-
cedures for preparation of 11–13 and their characterization, see
the ESI.†
Cmnm5(s2)U-modified anticodon arm domains (Fig. 1c)
were synthesized manually on a 5 µmol scale using commer-
cial tac-protected phosphoramidites of the canonical units and
a slightly modified version of Sproat’s protocol (ESI†).22 For
improving the overall yield of the oligomers, the couplings
were conducted in 8 molar excess of A, U, C, and G amidites
for 8 min, while the modified units were used in 12 molar
excess and coupled twice, each time using 6 molar excess of an
amidite and 12 min coupling time. Coupling yields were in the
range of 90–95%.
It is generally known that the 2-thiocarbonyl group of
2-thiouridine derivatives reacts with various oxidizing reagents
used in the oligoribonucleotide synthesis giving products of
2-thio → 2-oxo transformation and/or oxidative desulfurization
(s2 → H2).17,23,24 The scope and nature of the above-mentioned
side-processes strongly depend on C-5 substituents and the
oxidant nature.17,24 Consequently, an eﬀective and universal
protocol for the PIII → PV oxidation cycle has not been pub-
lished so far.
We tested several oxidizing reagents for the synthesis of the
cmnm5s2U-modified RNA oligomer using 2-thiouridine 12b
and a previously published methodology.17,18 We have found
that the 2-thiocarbonyl group of cmnm5s2U 12b remains intact
in a 0.02 M iodine (8 equiv.) solution in THF–H2O–pyridine,
23
in contrast to its easy oxidation with standard oxidizing
reagents (0.16 M I2–water, 1 M tert-BuOOH–ACN) or partial
loss of s2 with a diluted solution of tert-BuOOH (0.25 M) in
anhydrous toluene or acetonitrile.
In the first deprotection step the DMT group was removed
from the 5′-terminal residue and CPG-bound RNAs were
treated with TEA–ACN (1 : 1 v/v), and then with 8 M ethanolic
ammonia. The two-step deprotection procedure made it poss-
ible to avoid the reaction of heterobase residues with the
acrylonitrile generated during the deprotection of phosphate
residues.25 To remove the TBS and TMSE protecting groups,
the tetraalkylammonium salts were used. The 1 M solution of
Bu4NF gave the best result in desilylation of cmnm
5U-modified
RNA, while 1 M Et4NF turned out to be the most eﬀective desi-
lylating reagent for cmnm5s2U-modified RNA. The use of TEA
× 3HF gave only partial deprotection of the TMSE group in
accordance with previous observations.19 The fully deprotected
oligomers were quenched with phosphate buﬀer, desalted,
and then purified by preparative IE-HPLC (Fig. 2a, ESI†).
The desalted RNAs were lyophilized to yield 8.5 mg of
mt-ASLLeu(cmnm5U34) and 5 mg of mt-ASL
Lys(cmnm5s2U34).
The homogeneity and chemical structure of the synthetic
oligoribonucleotides were verified by MALDI-TOF data (ESI†)
as well as RNA enzymatic digestion (ESI†) to the expected
mixture of nucleosides, whose composition was tested by RP
HPLC, and the data were compared with those registered
under identical conditions for modified nucleosides20 as a
reference (Fig. 2c and d). As shown in Fig. 2c, HPLC elutions
monitored at 264 nm indicate that mt-ASLLeu and mt-ASLLys
contain cmnm5U (7.59 min) and cmnm5s2U (18.80 min),
respectively.
For the synthesis of cmnm5(s2)U-modified 17-mers (Fig. 1),
2-(p-nitrophenyl)ethyl (NPE)26 protection of the cmnm5(s2)U
carboxyl function was also used (experimental data not
shown). The RNA synthesis was conducted using the same pro-
tocol with the exception of oligomer deprotection (ESI†). The
use of NPE-protected cmnm5(s2)U amidites caused a signifi-
cant decrease of the oligomer eﬃciency in comparison with
the incorporation of TMSE-protected analogues (shorter and
partially deprotected oligomers were observed in HPLC). The
utilization of the NPE-strategy for the synthesis of the
cmnm5s2U-modified oligomer resulted in a complete desul-
phurization. It is likely that the strong basic DBU solution
required for NPE deprotection causes the s2 → o2 transform-
ation in the cmnm5s2U structure.
Fig. 2 (a) Anion-exchange HPLC of crude, deprotected mt-ASLLeuS. cerevisiae-
(cmnm5U34) and mt-ASL
Lys
S. cerevisiae(cmnm
5s2U34). (b) Analytical injection
of desalted and lyophilized oligoribonucleotides. (c) HPLC nucleoside
composition of mt-ASLs. (d) References of cmnm5U and cmnm5s2U
injected in control experiments.
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Conclusions
The 2-(trimethylsilyl)ethyl group (TMSE) was selected for pro-
tection of carboxyl acid residue of glycine and used for the
preparation of cmnm5U and cmnm5s2U phosphoramidites
(13a, 13b). TMSE blockage is compatible with the protection of
commercially available canonical monomeric units as well as
t6A, which is a natural modification located at position 37 of
yeast mt-ASLLys. Hypermodified monomers 13a and 13b were
eﬀectively incorporated into the anticodon arm sequences of
S. cerevisiae mt-tRNALeu and mt-tRNALys, respectively. The
reported procedure enables elimination of the unfavorable
desulphurization process in the case of cmnm5s2U incorpor-
ation which could significantly decrease the yield and purity of
the final product. Both oligomers have been obtained in
suﬃcient purity and quantity for NMR structural studies.
Future work will aim at the synthesis of the double modified
native sequence of mt-ASLLys(cmnm5s2U34, t
6A37).
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